FDA clears Tessie for noise aversion and separation anxiety in dogs

FDA approved Tessie (tasipimidine oral solution) on May 6, 2026, for the treatment of both noise aversion and separation anxiety in dogs, making it the first FDA-approved single drug product to carry both indications. The product is prescription-only, and the approval covers as-needed oral dosing for fear-based behavioral episodes tied to loud noises or owner departure. In FDA’s Freedom of Information summary, effectiveness for noise aversion was supported by a field study in 160 client-owned dogs, while separation anxiety data came from an 8-week field study in 224 client-owned dogs. The most commonly reported adverse reactions were vomiting and lethargy for noise aversion, and vomiting, diarrhea, and lethargy for separation anxiety. (fda.gov)

Why it matters: For veterinarians, the approval adds a new labeled option for two common, often overlapping canine anxiety presentations that can be difficult to manage in general practice. FDA also noted that behavioral modification remains important, and outside guidance from behavior medicine sources continues to support medication as an adjunct rather than a replacement for a treatment plan. That may make Tessie especially relevant for cases where pet parents need situational support for fireworks, traffic noise, or departures, but still need coaching on diagnosis, case selection, and follow-up. (fda.gov)

What to watch: Watch for launch timing, pricing, label uptake in primary care, and whether behavior specialists position Tessie mainly as a situational tool, or as part of broader multimodal anxiety management. (animaldrugsatfda.fda.gov)